Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this review is to describe the available data for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ward K, Citrome L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	akathisia weight gain second-generation antipsychotics atypical antipsychotics relapse-prevention Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5c1b5039e9ed40a3af76e91e8bf985ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c1b5039e9ed40a3af76e91e8bf985ed
record_format	dspace
spelling	oai:doaj.org-article:5c1b5039e9ed40a3af76e91e8bf985ed2021-12-02T00:26:55ZBrexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy1178-2021https://doaj.org/article/5c1b5039e9ed40a3af76e91e8bf985ed2019-01-01T00:00:00Zhttps://www.dovepress.com/brexpiprazole-for-the-maintenance-treatment-of-adults-with-schizophren-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia. This objective was completed by searching the databases PubMed, Embase, and ClinicalTrials.gov to identify relevant study results presented as papers or abstracts. In summary, brexpiprazole is a new agent in the D2 partial agonist class that has a unique receptor-binding profile, based in part on high affinity for serotonin 5HT1A and 5HT2A receptors, paired with lower intrinsic activity at dopamine D2 receptors. The average dose used in efficacy and safety studies for the maintenance treatment of schizophrenia ranged from 3.0 and 3.1 mg in the open-label safety studies to 3.6 mg in the double-blind randomized relapse-prevention study. Highlights from the 52-week double-blind placebo-controlled relapse-prevention trial evidenced rates of relapse in the brexpiprazole group of 13.5% vs 38.5% in the placebo group (number needed to treat 4, 95% CI 3–8; P<0.0001). Safety data indicate that brexpiprazole is tolerated well, with rates of discontinuation due to treatment-emergent adverse events that ranged from 5.2% of those taking brexpiprazole in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study. In the available trials, there were relatively low rates of akathisia, and the degree of weight gain was similar to that seen in studies with aripiprazole for the treatment of schizophrenia. Positive and Negative Syndrome Scale scores also remained relatively stable in the open-label safety studies. Available data indicate that brexpiprazole is an effective agent for the maintenance treatment of schizophrenia that is overall well tolerated. Keywords: akathisia, weight gain, second-generation antipsychotics, atypical antipsychotics, relapse preventionWard KCitrome LDove Medical Pressarticleakathisiaweight gainsecond-generation antipsychoticsatypical antipsychoticsrelapse-preventionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 247-257 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	akathisia weight gain second-generation antipsychotics atypical antipsychotics relapse-prevention Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	akathisia weight gain second-generation antipsychotics atypical antipsychotics relapse-prevention Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ward K Citrome L Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
description	Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia. This objective was completed by searching the databases PubMed, Embase, and ClinicalTrials.gov to identify relevant study results presented as papers or abstracts. In summary, brexpiprazole is a new agent in the D2 partial agonist class that has a unique receptor-binding profile, based in part on high affinity for serotonin 5HT1A and 5HT2A receptors, paired with lower intrinsic activity at dopamine D2 receptors. The average dose used in efficacy and safety studies for the maintenance treatment of schizophrenia ranged from 3.0 and 3.1 mg in the open-label safety studies to 3.6 mg in the double-blind randomized relapse-prevention study. Highlights from the 52-week double-blind placebo-controlled relapse-prevention trial evidenced rates of relapse in the brexpiprazole group of 13.5% vs 38.5% in the placebo group (number needed to treat 4, 95% CI 3–8; P<0.0001). Safety data indicate that brexpiprazole is tolerated well, with rates of discontinuation due to treatment-emergent adverse events that ranged from 5.2% of those taking brexpiprazole in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study. In the available trials, there were relatively low rates of akathisia, and the degree of weight gain was similar to that seen in studies with aripiprazole for the treatment of schizophrenia. Positive and Negative Syndrome Scale scores also remained relatively stable in the open-label safety studies. Available data indicate that brexpiprazole is an effective agent for the maintenance treatment of schizophrenia that is overall well tolerated. Keywords: akathisia, weight gain, second-generation antipsychotics, atypical antipsychotics, relapse prevention
format	article
author	Ward K Citrome L
author_facet	Ward K Citrome L
author_sort	Ward K
title	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
title_short	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
title_full	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
title_fullStr	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
title_full_unstemmed	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
title_sort	brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/5c1b5039e9ed40a3af76e91e8bf985ed
work_keys_str_mv	AT wardk brexpiprazoleforthemaintenancetreatmentofadultswithschizophreniaanevidencebasedreviewandplaceintherapy AT citromel brexpiprazoleforthemaintenancetreatmentofadultswithschizophreniaanevidencebasedreviewandplaceintherapy
_version_	1718403739714322432

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Ejemplares similares